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These antigen binding fragments, originating from Camelid heavy-chain antibodies, possess unusual hallmarks
in termsof (small) size, stability, solubility and speciﬁcity, hence allowing cost-effective production and sometimes
outperformingmonoclonal antibodies. In this review, we evaluate the current status of nanobodies to study, diag-
nose, visualize or inhibit cancer-speciﬁc proteins and processes. Nanobodies are highly adaptable tools for cancer
research as they enable speciﬁcmodulation of targets, enzymatic and non-enzymatic proteins alike.Molecular im-
aging studies beneﬁt from the rapid, homogeneous tumor accumulation of nanobodies and their fast blood clear-
ance, permitting previously unattainable fast tumor visualization. Moreover, they are endowed with considerable
therapeutic potential as inhibitors of receptor-ligand pairs and deliverers of drugs or drug-loaded nanoparticles
towards tumors. More in vivo and clinical studies are however eagerly awaited to unleash their full potential.
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Over the last decades, monoclonal antibodies (mAbs) against can-
cer-related transmembrane receptors, or their ligands, have found
their way to the clinic. mAbs can direct a cytotoxic payload towards
tumor cells, or radioactive orﬂuorescent tracers for PET/SPECT or optical
imaging, respectively. Their distribution and tumor penetration are
however limited due to mAb dimensions (~150 kDa, 10–15 nm long
and 7–9 nm wide). Moreover, their long half-life (ranging from daysry, Ghent University, Faculty of
Ghent, Belgium.
s).
. This is an open access article underto up to 4weeks) accounts for high background levels duringmolecular
imaging. In addition, host immune responses still remain an issue.
The variable fragments of Camelid heavy-chain only antibodies
(HcAbs), called nanobodies, may provide an answer to several of these
concerns (Hamers-Casterman et al., 1993) (Fig. 1A). Nanobody hall-
marks include small size (~15 kDa, 4 nm long and 2.5 nm wide), high
solubility, stability, speciﬁcity and afﬁnity, ease of cloning as well as
thermal and chemical resistance. Moreover, recombinant production
in microorganisms is very cost-efﬁcient and nanobodies can easily be
used as building blocks for multi-domain constructs (Muyldermans,
2013). These advantageous properties arise from their single domain
nature and from crucial amino acid mutations in the framework 2 re-
gion, rendering the overall structure more hydrophilic compared to
conventional antibody fragments (Fig. 1B). Their convex surface andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Representation of a heavy-chain antibody (HcAb) and its antigen binding fragment, called nanobody. A. In contrast to a monoclonal antibody (mAb), which comprises two heavy
and two light chains, an HcAb only contains heavy chains. AsHcAbs also lack one constant domain, the antigen binding region only consists of a single fragment, called a nanobody. The tail
region of the antibodies forms the Fc part and is able to trigger the immune system. B. Schematic representation (left) and conformation (right) of the nanobody entity, composed of
framework regions (FR1–4) alternated with three complementary determining regions (CDR1–3). Mutations in FR2 (stars) render the structure more hydrophilic as compared to
conventional antibody fragments. Moreover, the CDR3 loop is extended and enables recognition of hidden or buried epitopes.
41I. Van Audenhove, J. Gettemans / EBioMedicine 8 (2016) 40–48extended CDR3 loop further enables recognition of cavities or hidden
epitopes on the surface of the antigen (Fig. 1B). Combined with the
fact that nanobodies are considered to be non-immunogenic due to
their high similaritywith humanVH sequences, these unique properties
triggered numerous applications in fundamental research, diagnostics
and therapy (De Meyer et al., 2014; Chakravarty et al., 2014; Kijanka
et al., 2015; Muyldermans, 2013; Oliveira et al., 2013).
Nanobodies are stable in the reducing cytoplasmic environment and
when expressed as an intrabody they can modulate, trace and visualize
antigens (Muyldermans, 2013; De Meyer et al., 2014). Moreover, they
can serve as biomarker probes and when fused to radionuclides or
near-infrared ﬂuorophores they represent ideal non invasive in vivo im-
aging agents (Chakravarty et al., 2014; Oliveira et al., 2013). Therapeu-
tically, they can be utilized as neutralizing agents, as receptor-ligand
antagonists and as vehicles for effector delivery or targeted vehicle-
based drug therapy (Kijanka et al., 2015; Oliveira et al., 2013). Their de-
velopment as antagonists of extracellular disease-related targets is cur-
rently undergoing phase I, II and III clinical trials by Ablynx, the
company of which nanobodies are the trademark (http://www.
ablynx.com). Although nanobodies also aid in identifying new interest-
ing intracellular targets, their penetration through the cell membrane
remains a problematic issue for therapeutic targeting of cytosolic pro-
teins. In this review, we provide insight into the current status, ongoing
developments and future challenges towards successful implementa-
tion of nanobodies in the diagnosis and treatment of cancer.
2. Therapeutic Nanobodies Directed Against Extracellular Targets
In addition to ‘classical’ receptor targets such as EGFR (Roovers et al.,
2007,2011; Schmitz et al., 2013; Omidfar et al., 2013), HER2 (Jamnani et
al., 2012; Even-Desrumeaux et al., 2012), c-MET (Slordahl et al., 2013)
and VEGFR (Behdani et al., 2012), nanobodies against new targets
such as the DR5 death receptor (Huet et al., 2014; Papadopoulos et al.,
2015) and the chemokine receptors CXCR4 (Jahnichen et al., 2010)
and CXCR7 (Maussang et al., 2013; Blanchetot et al., 2013) come into
play. Alternatively, nanobodies can be generated against the cognate re-
ceptor ligands, such as HGF (for c-MET) (Vosjan et al., 2012), VEGF (forVEGFR) (Kazemi-Lomedasht et al., 2015; Ebrahimizadeh et al., 2015;
Farajpour et al., 2014), uPA (for uPAR) (Kaczmarek and Skottrup,
2015) or CXCL11/12 (for CXCR7) (Blanchetot et al., 2013) (Table 1).
Generally, one starts from a pool of nanobodies against the desired
target. Further selection is based on nanobody afﬁnity (nM) and the ca-
pacity to inhibit receptor-ligand binding or receptor activity in vitro.
Higher afﬁnity or avidity may be obtained by using a mixture of
nanobodies recognizing different epitopes at the surface of the same an-
tigen (oligoclonal) (Jamnani et al., 2012) or by using multivalent
nanobodies (Even-Desrumeaux et al., 2012; Huet et al., 2014), which
are usually linked in tandem via ﬂexible glycine-serine linkers
(Maussang et al., 2013; Huet et al., 2014). In addition, the nanobodies
are often evaluated against characterized mAbs by competition assays.
Remarkably, an anti-EGFR nanobody did not compete with Cetuximab
but structural studies demonstrated that it targets an epitope that
would not be accessible for theﬂattermAb paratope, pointing to the ad-
vantage of nanobodies to reveal new intervention points (Schmitz et al.,
2013).
To predict nanobody therapeutic efﬁcacy, preclinical cancer cell line
models are utilized in diverse experimental settings such as cell adhe-
sion, proliferation, migration, angiogenesis-like properties or perturba-
tion of speciﬁc signaling pathways. The small size of nanobodies is
conducive to deep(er) and homogenous tumor penetration but disad-
vantageous in terms of in vivo half-life (few hours). Therefore,
nanobodies are often linked to an anti-albumin nanobody, enabling
binding to serum albumin (~66 kDa) (Tijink et al., 2008; Vosjan et al.,
2012; Slordahl et al., 2013; Roovers et al., 2011; Maussang et al.,
2013). Several successful nanobody-based in vivo xenograft studies
with bispeciﬁc or multivalent nanobodies were reported, resulting in
delay of tumor growth (Vosjan et al., 2012; Roovers et al., 2011) or inhi-
bition of angiogenesis (Maussang et al., 2013). Such constructs some-
times outperform the corresponding mAb (Huet et al., 2014) but in
other cases they don't. For instance, a CONAN-1 nanobody could not
outperform Cetuximab, probably due to the lack of an Fc region and as-
sociated immune effector functions (Roovers et al., 2011). Adding an Fc
tail, as done before for other nanobodies (De Buck et al., 2013), could
provide a solution, but is not yet generally established. Although
Table 1
Overview on the distinct nanobody-based applications, their advantages and drawbacks when applied as therapeutics, drug delivery moieties, intrabodies, diagnostics and/or imaging tools. The different constructs discussed in this review are sum-
marized as well as the reported issues and proposed solutions for each particular application. See main text for more details and accompanying references. At right, the current status in terms of conducted in vitro, in vivo and clinical experiments is
given.
Nanobody constructs Nanobody advantages Reported issues Solution Current status
Nanobodies against
extracellular targets
Receptors as target
EGFR, HER2, c-MET, VEGFR, DR5,
CXCR4/7
Ligands as target
HGF, VEGF, uPA, CXCL11/12
Excellent domain building blocks
Deep & homogenous tumor accumulation
Target new epitopes
Low afﬁnity
Fast blood clearance
Lack of Fc
Immunogenicity
Nb mixtures or multivalent constructs
Fusion to anti-Albumin nanobody
Adding an Fc-tail
Humanization
In vitro+++
In vivo xenografts ++
Clinical trials + (aborted)
Therapeutic potential
Nanobodies for drug
delivery
Targets
VEGFR2, EGFR, c-MET, HER2, MUC1
Toxins to deliver
Pseudomonas exotoxin A
Particles to deliver
Liposomes, micelles, NANAPs,
polymersomes, polyplexes
Suited for conjugation
No Fc tail
Rapid tumor accumulation
Can act antagonistic itself
Poor solubility and/or stability of drugs
Fast blood clearance
Affecting mostly cell
growth/proliferation
Encapsulation in nanoparticles
PEGylation
Aiming for cell death effect
In vitro+++
In vivo xenografts ++
Clinical trials /
Therapeutic potential
Study of intracellular
protein function
Intracellular targets
Fascin, cortactin, CapG
β catenin, PKCε
Vimentin, GFP
Intracellular stability/activity
Domain/function speciﬁcmodulation
Easy to fuse: use as chromo or deloc constructs
Aid in drug discovery/rational drug design
Cell membrane penetration required
for therapeutic use
Use of EPEC
Spontaneously penetrating nanobodies
In vitro+++
In vivo xenografts +
Applicable for cell
biological research
Nanobodies to detect
cancer biomarkers
Extracellular biomarker targets
AFP, CAIX, PMSA
TAG-72, HER2
High stability
Easy to conjugate
Suitable in several applications: ELISA, PCR, IHC
Small size, enabling chip format
Reveal new intracellular biomarkers for IHC
Increased performance desired Application speciﬁc
Use nanobody mixture
In vitro+++
Applicable for diagnostic
purposes
Nanobodies for molecular
imaging Targets
PMSA, MMR, HER2, HGF, VCAM1,
CAIX, EGFR
Labeling
99mTc, 177Lu, 111In, 123I, 68Ga, 89Zr, 124I,
131I
Micro/nanobubbles
IRDye800CW, IRDye700DX
Rapid & homogenous tumor accumulation
Fast blood clearance
Easy conjugation
Early imaging, safe procedure
Combination imaging & therapy possible
Image-guided surgery becomes possible
Accumulation in kidneys
Accumulation in liver and spleen
Accumulation in liver and intestines
Remove His-tag
Co-inject gelofusin and/or lysine
Change chelating agent
Construct-speciﬁc
Administerunlabeled Nb
Later time point of imaging
In vitro+++
In vivo xenografts +++
In vivomouse models
+++
Clinical trials +
(successful)
Applicable for imaging
Therapeutic potential
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Fig. 2. Overview on nanoparticle types that can be decorated with nanobodies to mediate selective targeting. Liposomes are based on lipid bilayers, while micelles and albumin-based
NANAPs provide a hydrophobic core to encapsulate drugs. Polymersomes and polyplexes are synthetic polymer-based particles and represent relatively new vesicle types, of which
the latter can be used to compact DNA plasmids. PEGylation is generally performed to extend blood half-life. Maleimidyl groups or polymer chains at the distal end of PEG enable
conjugation with the nanobody.
43I. Van Audenhove, J. Gettemans / EBioMedicine 8 (2016) 40–48nanobodies are considered non-immunogenic, the generation of
antibodies against administrated nanobodies can be an issue, as
shown in an (aborted) clinical trial with anti-DR5 receptor nanobody
(Papadopoulos et al., 2015). Moderate humanization can be performed
to anticipate potential immune responses (Slordahl et al., 2013). De-
spite the high potential of nanobodies targeting other ligand-receptor
combinations such as VEGF-VEGFR, in vivo studies for those targets are
still wanting.
In summary, while nanobodies are advantageous in terms of eco-
nomical production, possibility of targeting unique epitopes and
multimerization capacity, the lack of an Fc tail or a lower afﬁnity can
sometimes render them less potent than their mAb counterparts. Hu-
manizationmight be required in some cases. However, as in vivo studies
and clinical trials are still lacking for most cases, comparison with
established mAbs is not yet fully possible (Table 1).
3. Nanobody-mediated Drug Delivery
Several researchers exploited currently available nanobodies against
tumor-speciﬁc receptors as conduits for delivering toxins or drugs to tu-
mors, thereby reducing nonspeciﬁc toxicity to normal cells and
diminishing side effects. The lack of an Fc tail is advantageous here, as
Fc-mediated clearance or a triggered immunogenic responsemight pre-
vent delivery of the cargo. A recent example of an immunotoxin is the
dimeric construct composed of an anti-VEGFR2 nanobody and a trun-
cated form of the Pseudomonas exotoxin A (PE38), cloned with a linker
in between (Behdani et al., 2013) (Table 1).
Most efforts are done in the ﬁeld of nanoparticles
(diameter b 200 nm), as encapsulation of drugs further overcomes
problems such as poor solubility, limited stability and rapid clearance
(Table 1). Carriers used include liposomes (Oliveira et al., 2010; van
der Meel et al., 2012,2013), micelles (Talelli et al., 2011,2013), albu-
min-based nanoparticles (NANAPs) (Altintas et al., 2013; Heukers et
al., 2014a) and polymer-based polymersomes (Zou et al., 2015) orpolyplexes (Sadeqzadeh et al., 2011) (Fig. 2). PEGylation is generally ap-
plied to extend blood half-life and the nanobody can be conjugated at a
maleimidyl group or at introduced polymer chains at the distal end of
the hydrophilic PEG block. The nanobody is chemically modiﬁed with
N-succinimidyl-S-acetylthioacetate (SATA) or coupled via cysteine
chemistry. Both methods do generally not affect nanobody binding ca-
pacity (Heukers et al., 2014a; Massa et al., 2014). On-site accumulation
of nanoparticles is facilitated by enhanced permeability and retention
(EPR), as tumors bear leaky blood vessels and defective lymph drainage.
Moreover, due to the presence of several nanobodies on the same parti-
cle surface, avidity comes into play (Huet et al., 2014). Mostly applied
for several particle formats is the anti-EGFR nanobody EGa1, which
acts antagonistically towards EGFR and thus not only contributes to
drug guidance but also to the therapeutic effect.
Van der Meel and co-workers conjugated the anti-EGFR nanobody
on the surface of liposomes, and this coincided with receptor-mediated
internalization of EGFR and thus EGFR downregulation (van derMeel et
al., 2012). Loading the liposomes with an anti-IGF-1R kinase inhibitor
AG538 additionally affected IGF-1R signaling and further increased the
inhibitory effect on cancer cell growth in vitro. However, signiﬁcant
growth inhibitionwas only observed for one of the two cell lines exam-
ined in a mouse xenograft model (van der Meel et al., 2013). The same
nanobody was applied by Talleli et al. to coat the surface of
thermosensitive, biodegradable polymeric micelles (Talelli et al.,
2011). These micelles already intrinsically inhibit tumor growth in
vivo, and this can be further increased by covalently encapsulating the
chemotherapeutic doxorubicin (Talelli et al., 2013). Correspondingly,
prolonged animal survival was observed. On the other hand,
nanobody-albumin nanoparticles (NANAPs) are considered biocompat-
ible and safe due to the abundance of the protein in serum. The
multikinase inhibitor 17,864was encapsulated in Ega1-coated NANAPs,
resulting in clathrin-mediated endocytosis, digestion of the particles in
the lysosomes, release of the inhibitor in the cytosol and reduced cancer
cell proliferation in vitro (Altintas et al., 2013). Recently, also NANAPs
44 I. Van Audenhove, J. Gettemans / EBioMedicine 8 (2016) 40–48decorated with anti-Met nanobodywere shown to be transported to ly-
sosomes for degradation, hence providing another system for lysosomal
drug delivery (Heukers et al., 2014a).
Nanobody-mediated targeting of artiﬁcial polymer-based vesicles
has also received increased attention in the last years. Both
polymersomes based on biocompatible PEG-b-PCL and functionalized
with anti-HER2 nanobody (Zou et al., 2015) as well as polyplexes com-
posed of PEGylated PEI conjugates and decorated with anti-MUC1
nanobody (Sadeqzadeh et al., 2011) enable selective cancer cell
targeting. Of note, the latter macromolecular entity enables compaction
of DNA plasmid and hence ‘transcriptional’ drug delivery as shown for
the truncated-Bid (tBid) killer DNA. When under control of a MUC1
promotor, administration of these DNA-containing polyplexes resulted
in elevated Bid/tBid expression as well as considerable cell death
(Sadeqzadeh et al., 2011).
Hence, nanobodies are very convenient tools for delivering toxic
cargos to cancer cells and are well-suited for chemical conjugation
onto different nanoparticle formats. Moreover, they can boost the ther-
apeutic effect when bearing intrinsic antagonistic activity. However, in
vitro and in vivo data are not yet available for all cases reported here
andmost of the effects concern inhibition of cell growth or proliferation
rather than effective cell death. When completely established, clinical
studies will have to shed light on the safety and efﬁcacy of these
nanobody-targeted carrier molecules (Table 1).
4. Nanobodies Against Intracellular Targets: Tools to Identify New
Targets and Springboard to Future Therapeutics
As nanobodies do not suffer from the reducing cytoplasmic environ-
ment, they can be utilized as intrabodies. Unlike siRNAs, nanobodies
provide the advantage of protein domain- and protein function-speciﬁc
modulation (similar to thewaydrugs act), enabling high resolution pro-
tein analysis compared to complete protein downregulation or eradica-
tion (Table 1). For example, a nanobody that inhibits fascin-mediated
actin bundling or a nanobody that targets the SH3 domain of the actin
branch regulator cortactin demonstrated that fascin bundling activity
is required for cancer cell invadopodium longevity whereas cortactin
SH3 domain functionality underpins invadopodia formation and activi-
ty (Van Audenhove et al., 2014). Similarly, a nanobody that prevents
CapG from regulating the length of actin ﬁlaments through capping
the (+) ends of actin polymers was found to impair in vitro invasion.
Moreover, this nanobody reduced lungmetastasis of human breast can-
cer cell xenografts by more than 90% (Van Impe et al., 2013). Further-
more, nanobodies inhibiting β-catenin-mediated Wnt signaling
(Newnham et al., 2015) and nanobodies inhibiting or activating PKCε
kinase (Summanen et al., 2012) were shown to function intracellularly.
They can be used in the future to gain insight into the respective path-
ways that they regulate. These types of nanobodies will contribute to
a better understanding of protein structure-function relationships and
might aid in the discovery or rational design of new therapeutic drugs
through medicinal chemistry.
Deliberate intracellular protein displacement for molecular studies
is relatively easy to achieve when considering a protein that is
overexpressed, but less obvious to elicit for a resident endogenous pro-
tein. Tagging a nanobody with a targeting sequence allows its displace-
ment, and that of its endogenous antigen, to virtually any compartment
or region in the cell, enabling researchers to study the correlation be-
tween protein location and function. This strategy is also a good alterna-
tive when there are no nanobodies available that inhibit a particular
function of the antigen. For example, a MOM (mitochondrial outer
membrane) tag anchors the nanobody and its interaction partner at
the mitochondria (Van Audenhove et al., 2014; Van Impe et al., 2013).
In this way, the endogenous protein can be ‘depleted’ from its normal
site(s) of action. Moreover, intrabodies can be fused to ﬂuorescent
tags such as GFP, yielding chromobodies, to enable visualization of pro-
tein localization and behavior as shown for actin binding proteins aswell as vimentin (Van Audenhove et al., 2014; Maier et al., 2015). Final-
ly, in the so-called ﬂuorescent-three-hybrid strategy, a GFP targeting
nanobody is anchored at a subcellular compartment such as the nucleus,
while the proteins of interest (bait and prey) are fused with GFP and
RFP, respectively (Herce et al., 2013). Interaction between bait and
prey results in their colocalization at the site of the GFP-recognizing
nanobody and this can be followed in real-time in living cells. As such,
this model can be used to study protein-protein interactions or to select
and evaluate inhibitors.
The observation that a nanobody targeting CapG, a cytoskeletal pro-
tein that is relatively unknown, drastically curtails breast cancer metas-
tasis in an orthotopic in vivo xenograft model (Van Impe et al., 2013) is
revealing. It suggests that there aremany drug targets other than GPCRs
or kinases/phosphatases, inhibition of which results in a more than siz-
able anti-metastatic effect. Moreover, targeting such downstream effec-
tors may be less prone to eliciting side effects and we predict that there
are many cytoplasmic proteins that are equally interesting from a ther-
apeutic point of view as CapG. A major obstacle however is nanobody
intracellular delivery (Table 1). Some recent advances provide the ﬁrst
clues to solve this problem. First, the type III protein-secretion system
(T3SS) of enteropathogenic E.coli (EPEC) enables injection of
nanobodies into the cytoplasm of (cancer) cells, as shown for the
CapG-inhibiting nanobody (Van Impe et al., 2013). The genes encoding
the ﬁlamentous injectisome have been transferred into the non-patho-
genic E. coliK-12 strain andwere shown to reconstitute into a functional
structure (Ruano-Gallego et al., 2015). Second, Li and co-workers
showed that nanobodies against GFAP (glial ﬁbrillary acidic protein,
an intermediate ﬁlament protein), a marker of astrocytes, can cross
the blood-brain-barrier both in vitro and upon injection in vivo, resulting
in diffusion into brain tissue and penetration into astrocytes (Li et al.,
2012). This suggests that nanobodies can be spontaneously cell pene-
trating under some circumstances (high pI) but the observation as
such necessitates independent conﬁrmation by others.
Thus, to turn nanobodies against intracellular targets into potent
therapeutics, future attempts should focus on their efﬁcient and safe
cellular membrane penetration. To obtain site-speciﬁc targeting, an in-
teresting possibility that remains to be investigated is the encapsulation
of recombinant nanobodies, or the compaction of nanobody plasmids,
into nanoparticles, decorated with for example anti-EGFR nanobodies.
5. Detecting or Deﬁning Cancer Biomarkers byMeans of Nanobodies
Apart from therapy, nanobodies can aid in early diagnosis and cancer
prevention by detecting or deﬁning biomarkers (Table 1). Nanobodies
can improve current mAb-based diagnostic techniques due to their
high speciﬁcity. Furthermore, their high stability under extremes of
temperature, pH, or ionic strength, as shown for the cancer biomarker
alpha-fetoprotein (AFP) (Chen et al., 2016), ensures that the application
still can occur under harsh conditions. Cell-based ELISA was successful
for nanobodies against the carbonic anhydrase IX enzyme (CAIX)
(Araste et al., 2014), prostate-speciﬁc membrane antigen PMSA (Zare
et al., 2014), tumor-associated glycoprotein 72 (TAG-72) (Sharifzadeh
et al., 2013) and HER2 (Jamnani et al., 2012). Of note, a better perfor-
mance was achieved with a mixture of several nanobodies. To perform
sandwich ELISA, both a capturing and detecting nanobody are used,
targeting different epitopes on the antigen. Nanobodies against AFP
reached a detection limit of 0.47 ng/mL. One step further, a chip format
sandwich ELISA with anti-HER2 nanobodies covalently bound onto a
screen-printed electrode (SPE) was proposed with a detection limit of
1 μg/mL (Patris et al., 2014). The most sensitive detection (0.0005 ng/
mL) could be achieved by means of immune-PCR with anti-AFP
nanobodies (Chen et al., 2016).
Due to the relative ease of single domain nanobody generation com-
pared to conventional antibodies, an elegant and fast strategy to gener-
ate nanobodies against (unknown) cancer biomarkers is by performing
immunization with patient samples. This strategy resulted in the
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(Even-Desrumeaux et al., 2012). Similarly, the technology of nanobody-
based reverse proteomics was used in glioblastoma multiforme (GBM)
(Jovcevska et al., 2014). By performing mass-spectrometry analysis on
nanobody-antigen pairs, the new GBM biomarkers TRIM28 and β-
actin could be revealed. As all thesemarkers are localized intracellularly,
they are especially proposed for immunohistochemical-based diagnos-
tic purposes.6. Nanobodies in Molecular Imaging
The small size of nanobodies is highly advantageous especially in the
ﬁeld of molecular imaging as it enables rapid tumor accumulation and
homogenous distribution aswell as efﬁcient blood clearance, contribut-
ing to high tumor-to-background ratios. Moreover, nanobodies can be
easily conjugated to several kinds of imaging agents and their high spec-
iﬁcity renders their use relatively safe.
Single-photon emission computed tomography (SPECT) is based on
γ-rays and nanobodies are here linked to radionuclides such as 99mTc,
177Lu, 123I and 111In. On the other hand, the positron-emitting radioiso-
topes 68Ga, 124I or 89Zr are used for positron emission tomography (PET)
purposes. Again, especially cancer-speciﬁc receptors such as EGFR
(Vosjan et al., 2011) and HER2 (D'Huyvetter et al., 2012; D'Huyvetter
et al., 2014; Xavier et al., 2013; Keyaerts et al., 2015; Massa et al.,
2014; Pruszynski et al., 2013; Pruszynski et al., 2014) (Table 1) are inter-
esting targets for tumor visualization. Recent research in this area fur-
ther focuses on PMSA (Chatalic et al., 2015; Evazalipour et al., 2014),
which is overexpressed in prostate cancer, and HGF (Vosjan et al.,
2012), which is implicated in several cancers, though also in cardiovas-
cular disease. Alternatively,Movahedi and coworkers raised nanobodies
against the macrophage mannose receptor MMR, which is highly
expressed by tumor-associated macrophages and thus serves as an al-
ternative strategy to image the tumor stroma, especially the hypoxic
areas (Movahedi et al., 2012).
Prior to radiolabeling, nanobodies are conjugated with bifunctional
chelating agents which possess a metal binding moiety for sequestra-
tion of the metallic radionuclide and are generally DPTA (acyclic)-,
DOTA (macrocyclic), or NOTA-based. Moreover, the chelating agents
are equipped with a chemically reactive functional group for attach-
ment to the nanobody, which can occur in several ways. First of all, ran-
dom conjugation can be performed via the free ε-amino-group on
nanobody lysines, as shown for the anti-HER2 and the anti-PMSA
nanobodies. Second, Massa and co-workers demonstrated a generic
strategy for site-speciﬁc labeling of nanobodies (Massa et al., 2014). To
this end, the anti-HER2 nanobody was cloned with a C-terminal un-
paired cysteine following its hexahistidine tag. A reduction step was
needed prior to conjugation due to spontaneous dimerization and cap-
ping of the unpaired cysteine. Subsequently, the reduced probe could be
bound to maleimide-DPTA, followed by labeling with 111In. Third, the
hexahistidine tag of the nanobody can be directly labeled with
99mTc(CO)3 without any chemical modiﬁcation of the protein, as
shown for an anti-PMSA nanobody and the anti-MMR nanobody
(Evazalipour et al., 2014;Movahedi et al., 2012). Site-speciﬁc orHis-me-
diated labeling has the advantage that antigen binding activity of the
nanobody is usually unaffected. When lysine residues involved in ran-
dom conjugation are located outside the antigen-binding loops, no in-
terference with antigen binding should be expected either (Xavier et
al., 2013; Keyaerts et al., 2015).
Selection of ‘lead’ components for further (pre)clinical testing usual-
ly occurs on the basis of production yield, afﬁnity and speciﬁcity, which
should always be re-evaluated in their (radionuclide) labeled format.
When internalization in cell line models is established, ﬁnal validation
is done in vivowith respect to tumor uptake, tumor-to-normal organ ra-
tios and fast blood clearance. As such, selected components enable im-
aging as early as 1 h post-injection, which contributes to patient safety.One drawback of this approach is the accumulation of radiolabeled
nanobodies in the kidneys and bladder (Table 1), which is in fact a typ-
ical characteristic for small radiolabeled proteins and peptides. After
glomerular ﬁltration (cut-off of 60 kDa), nonspeciﬁc reabsorption in
the proximal tubuli may account for the residence in kidneys. Remark-
ably, D'Huyvetter and co-workers showed that the highest accumula-
tion occurs with Myc-His-tagged anti-HER2 nanobody, followed by
His-tagged and ﬁnally untagged nanobody (70–88% less accumulation).
The amino acid composition and polarity at the C-terminus thus pre-
dominantly affect kidney retention (D'Huyvetter et al., 2014). This
could be diminished with 90–95% by co-injecting gelofusine, an inhibi-
tor of themegalin receptor responsible for tubular protein reabsorption.
Similarly, Chatalic and co-workers showed that renal uptake of their
His-tagged anti-PMSA nanobody could be reduced without loss of
targeting by co-injecting a combination of gelofusine and the positively
charged amino acid lysine or by removing the His-tag from the
nanobody (Chatalic et al., 2015). Also the untagged 68Ga-labeled anti-
HER2 nanobody showed a 50% drop in renal accumulation compared
to its His-tagged equivalent (Xavier et al., 2013). Another determining
parameter can be the type of chelating agent, as signiﬁcantly higher kid-
ney uptake was reported for the DOTA-based conjugates compared to
the DTPA-based conjugates of anti-HER2 nanobody (D'Huyvetter et al.,
2012). Finally, albumin binding via a second nanobody could be a strat-
egy to reduce renal retention, although this option is not preferred due
to increased blood residence time and thus increased radiation expo-
sure (Vosjan et al., 2012). For the case of 99mTc-labeled anti-MMR
nanobodies to visualize tumor-associated macrophages, the accumula-
tion was higher in liver and spleen (expressing MMR) as compared to
the tumor (Movahedi et al., 2012). The authors solved this by adminis-
tering an excess of unlabeled bivalent anti-MMRnanobody,which elim-
inates extratumoral signals while maintaining the targeting of tumor-
associated MMR-positive cells.
Currently, the best established nanobody-based imaging agent is the
68Ga-coupled anti-HER2 nanobody 2Rs15d for PET imaging (Xavier et
al., 2013). Preclinical evaluation revealed a good toxicological proﬁle
and a low radiation burden, enabling the construct to enter phase I clin-
ical trials on humans (Keyaerts et al., 2015). The construct scoredwell in
terms of efﬁciency, tracer accumulation and safety as no adverse effects
or antibodies against the administrated nanobody were detected, ren-
dering this construct suitable to enter phase II clinical trials. One draw-
back howeverwas the uptake of the agent in liver and intestines, next to
its expected accumulation in the kidneys. This might obscure liver me-
tastasis, although no suchmetastases were present in the patient group
and the question could thus not be solved. As the liver uptake decreases
over time, a later time point of imaging is proposed by the authors to
improve signal-to-noise ratio at the liver if needed (Keyaerts et al.,
2015).
When using β-emitting radioisotopes such as 131I and 177Lu, a ther-
apeutic effect can also be pursued by their ionization and DNA damag-
ing activity. Such a radionuclide-based construct enabling both
imaging and therapeutic use is termed ‘theranostic’. Gelofusin
coinfusion with untagged 177Lu-DTPA-anti-HER2 nanobody almost
completely blocked tumor growth in xenograft mouse models bearing
small tumors, coinciding with increased event-free survival
(D'Huyvetter et al., 2014). Moreover, non-speciﬁc radiation to healthy
tissues was absent. Although the system causes a comparable radiation
level for both tumor and kidneys, histopathological analyses of renal tis-
sue revealed no visible toxicity, although long-term events cannot be
excluded (D'Huyvetter et al., 2014). Characterization of this agent
should be continued in clinical trials to highlight the potential of
radiolabeled nanobodies as a valuable therapy. Also the radio-iodinated
131I-anti-HER2 nanobody shows potential for treatment of HER2-over-
expressing malignancies (Pruszynski et al., 2013). Residualizing agents
are used for radioiodination to avoid lysosomal degradation after
receptor-mediated internalization, which would result in rapid loss
of radioactivity. Such agents (for example containing guanidine or
46 I. Van Audenhove, J. Gettemans / EBioMedicine 8 (2016) 40–48D-glutamates) render the construct ‘charged’ in lysosomes to prevent its
diffusion across membranes and further avoid action of deiodinases.
However, also very high radioactive levels were observed in the kidneys
for the resulting constructs. The authors showed later on that radio-io-
dination via another method was superior in terms of tumor retention
and coincided with lower uptake in normal tissues including the kid-
neys (Pruszynski et al., 2014), pointing to the importance of optimizing
the labeling method.
Tumor imaging can also be performed by means of ultrasound
waves, which are reﬂected differently according to the organ or tissue.
Microbubbles are generally used as contrasting agents and nanobody-
mediated guidance can further aid in improving contrast at the desired
location. Recent examples include microbubbles decorated with anti-
VCAM-1 nanobody for detection in the tumor vasculature (Hernot et
al., 2012), and nanobubbles with anti-PMSA nanobody targeting
PMSA-positive cells in vitro as well as in a mouse xenograft (Fan et al.,
2015).
To avoid ionizing radiation, nanobodies can also be conjugated to
near-infrared ﬂuorophores such as IRDye800CW to perform optical
tumor imaging, a technique that is cost-effective, ﬂexible, sensitive
and fast. As such, a nanobody against the hypoxia marker enzyme
CAIX and an anti-EGFR nanobody were used for molecular imaging of
(pre-) invasive breast cancer and orthotopic oral squamous cell carcino-
ma (OSCC), respectively (van Brussel et al., 2015; van Driel et al., 2014)
(Table 1). The brightest future of this technique lies in imaging-guided
surgery, which was ﬁrst shown with anti-HER2 nanobodies. Under the
guidance of real-time ﬂuorescent images, surgical resection of a HER2-
positive mouse xenograft could be demonstrated (Kijanka et al.,
2013). Also for CAIX and EGFR targeting, tumor margins could be delin-
eated already 2 h after nanobody administration with good tumor-to-
background ratios in mouse models (van Brussel et al., 2015; van Driel
et al., 2014). When using a photosensitizer ﬂuorophore instead, such
as IRDye700DX, speciﬁc cell death can even be induced upon light-me-
diated activation (Heukers et al., 2014b).
From the panoply of nanobody-based technologies directed at diag-
nosis and/or cancer treatment, the use of nanobodies in molecular im-
aging is the most promising due to its combination of all the
advantages compared to current mAb based techniques, the swiftness
and the safety of the procedure and the current status of this application
(Table 1). Moreover, high nanobody-mediated speciﬁc radioactive de-
position renders these constructs extremely suitable for therapeutic ac-
tion on micrometastases and minimal residual disease.7. Outstanding Questions
Although the potential of nanobodies against extracellular targets is
high, both in the form of antagonistic nanobodies or nanobody-decorat-
ed nanoparticles (Table 1), further (pre)clinical studies should be per-
formed to reveal their true potential in the clinic. The ﬁrst clinical
trials with anti-receptor or anti-ligand nanobodies apart from the DR5
receptor are eagerly awaited.
Especially the combination with transcriptional targeting via com-
plexed plasmid deserves more attention, as this would open up a new
era of applications. Moreover, this could aid in the still unsolved cell
penetration problem for nanobodies against intracellular targets. Plas-
mid delivery via a safe drug carrier such as albumin-based NANAPs
would circumvent many issues and enable delivery of virtually all
kinds of constructs.
The usefulness of nanobodies targeting cytoplasmic proteins in gen-
eral should not be underestimated. Researchers have found their way to
these nanobodies for use in super-resolution microscopy in their re-
combinant format (Mikhaylova et al., 2015). As such, they allow sin-
gle-particle trafﬁcking to study protein function, localization and
dynamics with a previously unattainable precision. Furthermore, as
intrabodies, they show advantages compared to siRNA in cell biologicalresearch due to the ability to target domain-speciﬁc functions. Although
this is not directly applicable in the clinic, these studies can indirectly
aid in rational drug design by revealing the residues or surfaces that
should be targeted by a small compound to mimic the effect triggered
by the nanobody, hence accelerating drug development. More general-
ly, X-ray co-crystal structures between a nanobody and its antigen, be it
a cytoplasmic protein or transmembrane receptor, is thought to help
drug development viamedicinal chemistry but the ﬁrst such compound
remains to be discovered. Ultimately, such considerations would not be
required if the membrane would be permeable to a nanobody. Despite
isolated cases, this is not a general feature and chemical modiﬁcations
will possibly be inevitable.
8. Search Strategy and Selection Criteria
Data for this Review were identiﬁed by searches of Sciencedirect,
NCBI, PubMed, and references from relevant articles using the search
terms “cancer” or “tumor” and “nanobody” or “VHH” in the abstract,
title or keywords. Only articles published in English between 2010
and 2016 were included.
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